Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Enclosed is a plethora of leading edge AZ materials. Enjoy!
https://www.scientificamerican.com/custom-media/the-new-age-of-alzheimers/
WGT!
I have to say that all the current AVXL negativity reminds of another stock that I am involved with: AMD. Just like AMD which ran up to $100, AVXL had a runup to $30.00, only to be decimated in the following years to the current price at $4.20, AMD was badly beaten by negativity and retreated to $2.00.
AMD price ihas since recovered and exploded through the previous high of $100.00 and closed today at $167.00. I wholly anticipate that the AVXL price will rebound strongly as well, through $30 and much higher!
WGT!
Music to my ears:
TGD pointed out that recently the world approval guidelines have been transformed and now align with AVXL outcomes especially the requirement of only one endpoint being required to meet approval standards.
TGD suggested that ease of administration of oral (liquid or solid) blarcamesine and its outperformance compared to the competition sets blarcamesine apart as a potential world leader. Additionally, blarcamesine offers a HUGE administrative cost advantage over would be competitors.
TGD also reasserted that AVXL management are continuing to explore the most efficient means of marketing blarcamesine once approved.
Not too shabbly performance for a neophyte bio pharma upstart!
How is it possible that the AVXL price languishes at current levels when such HUGE potential exists?
WGT!
Perhaps the volume at the close of trading 6,455,896 shares has established a large base from which to launch over the next couple of weeks?
Would really enjoy seeing AVXL close at or near its day high today. After all, AVXL is overdue for a reversal of price trend and a closing of the $7 to $10 overhead gap.
WGT!
No PR = no material news = no problem.
The gap between $7 and $10 may well be rapidly filled when imminent positive news is released.
WGT!
Hey plex, it posts a blurb about the best stocks for 2024. AVXL is the 2nd one listed.
Yes nidan7500, a price trend reversal beginning early this week is welcomed. My favourite indicator, the 30 day RSI, is strongly oversold. A climb back to $10 in March/April does look doable!
I hear you! One needs to see the value which the market might come to realize at any moment.
Thanks sage4 for the additional examples of cash strapped biotechs.
I have been accumulating shares in Theralase (tlt.v) who I believe have a product that fills a niche better than its competitors. They are at the opposite end of the dollar continuum to AVXL, as they are extremely strapped for cash but not unlike AVXL, they have a very competitive product based upon indicators to date. Oh how they wish they had $150 million in cash without debt. By buying cash strapped I'm thinking that if they can limp across the finish line in the next couple of years, my analysis suggests HUGE price escalation from the current $0.20. Thankfully, the insiders put up significant cash in the past week to keep it afloat.
Hopefully, it is bought out within the next year or two.
Tough beginning to the new year for AVXL shareholders to be sure as RETT results, on the surface, did not meet market expectations.
Need TGD to present some good news on Wednesday in order to reverse this year's negative trend. Let us know that RETT is still in play with the FDA and also let us know what progress has been made with the EMA AZ application.
I see the 30 day RSI is well into oversold territory so any positive news will be welcomed in order to reverse the negative downturn and close that Jan 2/24 gap.
Let's make 2024 the WGT! year!
Just a great post! Clearly delineates how Blarcamesine is currently the AZ frontrunner.
Thanks Autophagy and Mayo.
WGT!
A2-73 had a broad spectrum of endpoints and biomarkers and outperformed all existing drugs. You do not need any maintenance, no needles, and need routine tests, which according to the EMA, is a major advantage for Blarcamesine and even more so for rural users.
Is the above statement true or false?
WGT!
Is the captioned statement true or false?
WGT!
Wow rayovac812, What a great post! One hundred recommendations.
Longs need to keep their focus on the captioned statement as their primary benchmark for measuring Blarcamesine performance and not be swayed by the barrage of (intentionally?) misleading comments by those who are negatively motivated for whatever reason.
WGT!
Yes tradeherpete, We are now being offered some colour on the seemingly out of the blue $14 billion reference by TGD at the JPM conference.
Looking foward to the time when Mr. Market sniffs out AVXL potential.
WGT!